Synopsis
An unprecedented push to manufacture billions of doses this year alone has led to supply bottlenecks, putting firms such as Pfizer and AstraZeneca Plc in the firing line of angry government customers. Now the industry is taking heat for closely guarding its intellectual property.

The discovery of multiple safe and effective Covid-19 vaccines has been the reputational boost the pharmaceutical industry needed. As science has caught up to the coronavirus, the price-inflating antics of Martin Shkreli and manufacturers’ roles in the opioid epidemic have faded into the background while people literally raise their glass to drugmakers like Pfizer.

An unprecedented push to manufacture billions of doses this year alone has led to supply bottlenecks, putting firms such as Pfizer and AstraZeneca in the firing line of angry government customers. The potential adverse effects of sticking needles into people’s arms are dominating headlines, as seen with the halting of the Astra vaccine in Canada and Europe even as regulators insist the benefits outweigh the risks.

Now the industry is taking heat for closely guarding its intellectual property. That’s blamed for what the World Health Organization dubs a “catastrophic moral failure”: the immunization gap between the developing world and deep-pocketed rich countries, which have ordered enough doses to cover their populations several times over.

If vaccine makers were to waive exclusive rights to manufacture their product – an idea pushed by 58 countries at the World Trade Organization including India and South Africa – advocates say that supply would bloom and we would exit the pandemic quicker. The push for a “people’s vaccine,” backed by the likes of Bernie Sanders, is popular with three-quarters of British voters and almost two-thirds of French people polled by YouGov.

Unlike in past crises such as HIV/AIDS, cracking open the recipe for Covid vaccines, especially those from Pfizer and Moderna is only half the battle given the complexity of genetic technologies making their debut in this pandemic. Manufacturing is a challenge too, and there isn’t much time for trial and error.

We haven’t quashed this virus yet and letting the pharma industry’s pandemic halo crash to the floor won’t help get us there any faster. Finding constructive ways to keep the public’s romance with drugmakers last a little longer makes sense, even if it doesn’t make money.

Read more at:
https://economictimes.indiatimes.com/news/international/world-news/short-lived-romance-pharma-industry-facing-heat-for-covid-vaccine-failures-greed/articleshow/81775786.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

More News
Lynparza shows promise in preventing cancer recurrence
News · 16/06/2021

AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

READ MORE
Is ammonia the fuel of the future?
News · 15/06/2021

Ammonia saved the world once; it might do it again. A century ago, the world faced a looming food crisis. A booming population was pushing farmers to grow crops faster than nitrogen-fixing bacteria in the soil could keep up, and the South American deposits of guano and natural nitrates they applied as fertilizer were dwindling.

READ MORE
Lipids – The unsung vaccine component
News · 15/06/2021

Lipids are an unsung component in the two mRNA-based shots, the only vaccines to be approved so far in the US. Naked mRNA quickly degrades in the body and can trigger an unwanted immune reaction. To get the genetic material to its target cells, vaccine developers combine it with a mixture of several sophisticated lipids to form lipid nanoparticles, or LNPs. mRNA vaccine producers use a package of 4 lipids to formulate their LNPs

READ MORE
Australian Vaccine First In World To Show Ability To Totally Block Covid-19 Virus Transmission
News · 01/06/2021

Australian company, Vaxine Pty Ltd, has developed a protein based COVID-19 vaccine that completely blocks virus transmission to non-immune individuals.

READ MORE
As consciousness about nutrition, health rises in post-COVID world, demand for Organic Food is set to surge
News · 01/06/2021

If one positive could be drawn out of the devastating global COVID 19 crisis, it is the fact that this calamitous pandemic has made people more conscious about the need for healthier lifestyles, nutrition as well as their environmental footprint.

READ MORE
India’s Covid crisis & its impact on Global Shipping
News · 01/06/2021

India’s devastating Covid-19 crisis is threatening operations at some of its biggest ports, raising concerns. The action could trigger shipping delays that reverberate through global supply chains.

READ MORE
Khaana Chahiye | Fighting Hunger in Mumbai
News · 19/05/2021

A team of driven, concerned, caring citizens who decided to make a difference!

READ MORE
Molnupiravir – An investigational antiviral treatment developed in oral dosage form to fight against coronavirus and future pandemics:
News · 03/05/2021

Over the last year, several drugs have either been developed or tested to treat coronavirus. Now there’s another new antiviral drug that’s showing some promise by demonstrating ability to stop SARS-CoV-2 transmission within 24 hour!

READ MORE
What is just beyond the horizon for shipping in the rest of 2021 & 2022?
News · 03/05/2021

Looking within a short-term horizon, the outlook for container shipping over the next 2-3 months appears relatively well-known, although certainly not well-liked by shippers. In essence, we will continue to see a situation of bottleneck problems, capacity shortages and high pressure on rates. This is, hopefully, not a surprise to anyone now.

READ MORE